UNASSIGNED: Background To assess the efficacy and safety of @entity1945 and @entity786 (TC) in adult @entity1 with @entity242 subtypes who failed induction chemotherapy. @entity1 and methods @entity1 with @entity242 subtypes, refractory to or relapsed after at least one prior induction chemotherapy, inoperable, ECOG PS 0-2, with measurable, @entity74 ( @entity74 ), adequate organ functions, who have been treated with TC combination were retrospectively analysed within the AIO and SAREZ/BMBF network. Results Thirty-nine @entity1 , median age 28  years (18-58), 14 females, 25 males, have been identified. All @entity1 had received induction treatment according to (inter)national study protocols. Second-line TC was applied in 33 @entity1 (>= 3rd-line in 6 @entity1 ). Twenty-three @entity1 had refractory disease (evidence of @entity74 during induction chemotherapy); 8 @entity1 experienced an early relapse within 6  months as well as 8 @entity1 after more than 24  months (late relapse). A median of 3 cycles (range, 1-6) had been applied and antitumor activity was: CR 2.6  %, PR 7.9  %, and disease stabilisation ( @entity168 ) 26.3  %. PR lasted 32.8  months and median duration in @entity1 with @entity168 was 5  months (range, 2.0-14.7). The 3/6-months progression-free rates were 43.2 and 18.9  %. Conclusions Limited activity was seen in adult pts with refractory or relapsed @entity242 with the regimen which has proven activity in pediatric @entity1 . Adults with @entity18782 appear to have a similar dismal outcome as seen in pts with common adult-type histologies; however, a subset of @entity1 has achieved long-lasting remissions on TC resulting in long-term survival.

@entity1945 plus @entity786 in adults with relapsed or refractory XXXX : a retrospective analysis from the German Sarcoma Medical Oncology Group (AIO).

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity242 :: ('MESH:D012509', 'Disease') :: ['pediatric-type sarcoma', 'pediatric-type sarcomas', 'pediatric sarcoma'] @entity168 :: ('MESH:D029461', 'Disease') :: ['SD'] @entity18782 :: ('MESH:D018228', 'Disease') :: ['refractory small cell sarcoma'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity74 :: ('MESH:D030342', 'Disease') :: ['PD', 'progressive disease'] @entity1945 :: ('MESH:D019772', 'Chemical') :: ['topotecan']
@entity242 :: (MESH:D012509,Disease) :: ['pediatric-type sarcoma']
